FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025843504> ?p ?o ?g. }

• W2025843504 endingPage "538" @default.
• W2025843504 startingPage "532" @default.
• W2025843504 abstract "The inhibitor of apoptosis protein, XIAP, is frequently overexpressed in chemoresistant human tumours. An antisense oligonucleotide (AEG 35156/GEM 640) that targets XIAP has recently entered phase I trials in the UK. Method validation data are presented on three pharmacodynamic assays that will be utilised during this trial. Quantitative RT-PCR was based on a Taqman assay and was confirmed to be specific for XIAP. Assay linearity extended over four orders of magnitude. MDA-MB-231/U6-E1 cells and clone X-G4 stably expressing an RNAi vector against XIAP were chosen as high and low XIAP expression quality controls (QCs). Within-day and between-day coefficients of variation (CVs) in precision for cycle threshold (CT) and delta CT values (employing GAPDH and beta 2 microglobulin as housekeepers) were always less than 10%. A Western blotting technique was validated using a GST-XIAP fusion protein as a standard and HeLa cells and SF268 (human glioblastoma) cells as high and low XIAP expression QCs. Specificity of the final choice of antibody for XIAP was evaluated by analysing a panel of cell lines including clone X-G4. The assay was linear over a 29-fold range of protein concentration and between-day precision was 29% for the low QC and 23% for the high QC when normalised to GAPDH. XIAP protein was also shown to be stable at -80 degrees C for at least 60 days. M30-Apoptosense plasma Elisa detects a caspase-cleaved fragment of cytokeratin 18 (CK18), believed to be a surrogate marker for tumour cell apoptosis. Generation of an independent QC was achieved through the treatment of X-G4 cells with staurosporine and collection of media. Measurements on assay precision and kit-to-kit QC were always less than 10%. The M30 antigen (CK18-Asp396) was stable for 3 months at -80 degrees C, while at 37 degrees C it had a half-life of 80-100 h in healthy volunteer plasma. Results from the phase I trial are eagerly awaited." @default.
• W2025843504 created "2016-06-24" @default.
• W2025843504 creator A5003859308 @default.
• W2025843504 creator A5033620799 @default.
• W2025843504 creator A5039337111 @default.
• W2025843504 creator A5052081777 @default.
• W2025843504 creator A5055792960 @default.
• W2025843504 creator A5060487287 @default.
• W2025843504 creator A5066278436 @default.
• W2025843504 creator A5067426680 @default.
• W2025843504 date "2005-02-01" @default.
• W2025843504 modified "2023-10-18" @default.
• W2025843504 title "Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP" @default.
• W2025843504 cites W1513115519 @default.
• W2025843504 cites W1515542254 @default.
• W2025843504 cites W1567491890 @default.
• W2025843504 cites W1599411566 @default.
• W2025843504 cites W168517665 @default.
• W2025843504 cites W1745634660 @default.
• W2025843504 cites W1965682168 @default.
• W2025843504 cites W1967577655 @default.
• W2025843504 cites W1969442168 @default.
• W2025843504 cites W1990693536 @default.
• W2025843504 cites W2002227117 @default.
• W2025843504 cites W2006077720 @default.
• W2025843504 cites W2015778968 @default.
• W2025843504 cites W2016724271 @default.
• W2025843504 cites W2027107549 @default.
• W2025843504 cites W2037356096 @default.
• W2025843504 cites W2054164997 @default.
• W2025843504 cites W2071300214 @default.
• W2025843504 cites W2077642753 @default.
• W2025843504 cites W2084948372 @default.
• W2025843504 cites W2087389494 @default.
• W2025843504 cites W2089601738 @default.
• W2025843504 cites W2093730092 @default.
• W2025843504 cites W2094985040 @default.
• W2025843504 cites W2095022409 @default.
• W2025843504 cites W2098042588 @default.
• W2025843504 cites W2098975407 @default.
• W2025843504 cites W2110260685 @default.
• W2025843504 cites W2113211717 @default.
• W2025843504 cites W2119620663 @default.
• W2025843504 cites W2123247959 @default.
• W2025843504 cites W2134367544 @default.
• W2025843504 cites W2139531225 @default.
• W2025843504 cites W2147181531 @default.
• W2025843504 cites W2152852483 @default.
• W2025843504 cites W2170981092 @default.
• W2025843504 cites W2171317213 @default.
• W2025843504 cites W2172236291 @default.
• W2025843504 cites W2182806719 @default.
• W2025843504 cites W2323633757 @default.
• W2025843504 cites W4255020141 @default.
• W2025843504 cites W4355260 @default.
• W2025843504 doi "https://doi.org/10.1038/sj.bjc.6602363" @default.
• W2025843504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2362094" @default.
• W2025843504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15685240" @default.
• W2025843504 hasPublicationYear "2005" @default.
• W2025843504 type Work @default.
• W2025843504 sameAs 2025843504 @default.
• W2025843504 citedByCount "74" @default.
• W2025843504 countsByYear W20258435042012 @default.
• W2025843504 countsByYear W20258435042013 @default.
• W2025843504 countsByYear W20258435042014 @default.
• W2025843504 countsByYear W20258435042015 @default.
• W2025843504 countsByYear W20258435042016 @default.
• W2025843504 crossrefType "journal-article" @default.
• W2025843504 hasAuthorship W2025843504A5003859308 @default.
• W2025843504 hasAuthorship W2025843504A5033620799 @default.
• W2025843504 hasAuthorship W2025843504A5039337111 @default.
• W2025843504 hasAuthorship W2025843504A5052081777 @default.
• W2025843504 hasAuthorship W2025843504A5055792960 @default.
• W2025843504 hasAuthorship W2025843504A5060487287 @default.
• W2025843504 hasAuthorship W2025843504A5066278436 @default.
• W2025843504 hasAuthorship W2025843504A5067426680 @default.
• W2025843504 hasBestOaLocation W20258435041 @default.
• W2025843504 hasConcept C104317684 @default.
• W2025843504 hasConcept C123894998 @default.
• W2025843504 hasConcept C153911025 @default.
• W2025843504 hasConcept C185592680 @default.
• W2025843504 hasConcept C190283241 @default.
• W2025843504 hasConcept C2777408456 @default.
• W2025843504 hasConcept C31573885 @default.
• W2025843504 hasConcept C33195913 @default.
• W2025843504 hasConcept C40767141 @default.
• W2025843504 hasConcept C502942594 @default.
• W2025843504 hasConcept C55493867 @default.
• W2025843504 hasConcept C86803240 @default.
• W2025843504 hasConcept C98424977 @default.
• W2025843504 hasConceptScore W2025843504C104317684 @default.
• W2025843504 hasConceptScore W2025843504C123894998 @default.
• W2025843504 hasConceptScore W2025843504C153911025 @default.
• W2025843504 hasConceptScore W2025843504C185592680 @default.
• W2025843504 hasConceptScore W2025843504C190283241 @default.
• W2025843504 hasConceptScore W2025843504C2777408456 @default.
• W2025843504 hasConceptScore W2025843504C31573885 @default.
• W2025843504 hasConceptScore W2025843504C33195913 @default.

• next